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Abstract 
We have investigated the effect of nicotinic receptor ligands in the behavioral 
sensitization (hyperlocomotion) and rewarding properties (conditioned place preference 
paradigm, CPP) of 3,4-methylenedioxy-methamphetamine (MDMA) in mice. Each 
animal received intraperitoneal pretreatment with either saline, dihydro--erythroidine 
(DHE, 1 mg/Kg) or varenicline (VAR, 0.3 mg/Kg), 15 min prior to subcutaneous 
saline or MDMA (5 mg/Kg), for 10 consecutive days. On day 1, both DHE and VAR 
inhibited the MDMA-induced hyperlocomotion. After 10 days of treatment, MDMA 
induced a hyperlocomotion that was not reduced (rather enhanced) in antagonist-
pretreated animals. This early hyperlocomotion was accompanied by a significant 
increase in heteromeric nicotinic receptors in cortex that was not blocked by DHE or 
VAR. Behavioral sensitization to MDMA was  highest 2 weeks after the discontinuation 
of MDMA treatment. This additional increase in sensitivity was prevented in animals 
pretreated with DHE or VAR. At this time, MDMA-treated mice showed a significant 
increase in heteromeric receptors in cortex that was prevented by DHE and VAR. An 
involvement of α7 nicotinic receptors in this effect is ruled out.  
MDMA (10 mg/Kg) induced positive CPP that was abolished by DHE (2 mg/Kg) and 
VAR (2 mg/Kg). Moreover, chronic nicotine pretreatment (2 mg/Kg, ip, b.i.d., for 14 
days) caused MDMA, administered at a low dose (3 mg/kg), to induce CPP, which 
would otherwise not occur. Finally, present results point out that heteromeric nicotinic 
receptors are involved in locomotor sensitization and addictive potential induced by 
MDMA. Thus, varenicline might be a useful drug to treat both tobacco and MDMA 
abuse at once. 
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1. Introduction 
MDMA1 is a synthetic drug that has properties of both stimulants and hallucinogens. 
Compared to other amphetamine derivatives, MDMA triggers a larger increase in 
serotonin and a smaller increase in dopamine release (Johnson et al., 1986). The 
behavioral and neurochemical adaptations related to chronic MDMA treatment are 
largely unknown. For instance, an increase in the functionality of cortical 5-HT2A and a 
decrease in striatal D2 receptors in mice treated with MDMA have been described 
(Varela et al., 2011). Many drugs of abuse, at low doses, can increase motor behavior 
producing heightened locomotion and exploration (Wise and Bozarth, 1987) and, after 
repeated administration, behavioral sensitization can arise from various 
neuroadaptations in multiple brain nuclei. This is not only the result of distinct 
molecular targets for the drugs, but may also include a differential involvement of 
learned associations. It is postulated that the relatively more robust pharmacological 
capacity of amphetamine derivatives to release dopamine may induce a form of 
sensitization that is more dependent on adaptations in mesoaccumbens dopamine 
transmission in comparison to cocaine and morphine sensitization (Vanderschuren and 
Kalivas, 2000).  
There is evidence that acetylcholine plays an important role in the hyperlocomotor 
activity induced by psychostimulants (Williams and Adinoff, 2008). Dihydro--
erythroidine (DHβE), a high-affinity competitive antagonist of 4 subunit-containing 
nAChR (nicotinic acetylcholine receptor) inhibits the induction of locomotor 
sensitization to d-amphetamine (Karler et al., 1996; Schoffelmeer et al., 2002). 
Moreover, knockout mice lacking the β2 nAChR subunit do not self-administer nicotine 
(Picciotto et al., 1999) and show less cocaine-conditioned place preference than wild-
type mice (Zachariou et al., 2001). All of these results indicate that heteromeric α4β2 
nAChR subtypes appear to play an essential role in nicotine dependence (Govind et al., 
2009); in this regard, an activation of α4β2 nAChR is strongly associated with 
dopamine release in the nucleus accumbens (NAcc) (Champtiaux et al., 2003)  and with 
drug-seeking behavior (Balfour et al., 2000; Picciotto et al., 1999).  A particular feature 
of nAChR is that chronic exposure to nicotine and other nicotinic ligands induces a 
higher level of epibatidine binding (up-regulation) that can lead to an increase in 
                                                          
1 Abbreviations: AUC, area under the curve; CPP, conditioned place preference; DHE, dihydro--erythroidine; 
MDMA, 3,4-methylenedioxy-methamphetamine; MLA, methyllycaconitine; NAcc, nucleus accumbens; nAChR, 
nicotinic acetylcholine receptors; VAR, varenicline; VTA, ventral tegmental area. 
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receptor function (functional up-regulation) (reviewed by Gaimarri et al., 2007). 
Therefore, the up-regulation of heteromeric nAChR could, via dopamine release, 
explain the reinforcing effect of nicotine on the mesolimbic system mediating nicotine 
addiction (Balfour et al., 2000). 
Studies examining the interactions between nAChR and psychostimulant drugs have 
focused primarily on d-amphetamine and cocaine but it is unclear whether such findings 
can be extended to other psychostimulants. Previous results from our group (for a 
review see Pubill et al., 2011) have demonstrated that nAChR are a pharmacological 
target for both methamphetamine and MDMA and are involved in some actions of these 
drugs of abuse such as analgesia or locomotor activity (Camarasa et al., 2009), tumor 
necrosis factor alpha suppression (Camarasa et al., 2010) and neurotoxicity (Chipana et 
al., 2008b; 2008c; Escubedo et al., 2009). We have described the direct and specific 
interaction of MDMA with α7 and α4β2 nAChR in mouse brain membranes and 
cultured PC12 cells (García-Ratés et al., 2007). The interaction with nAChR occurs at 
low micromolar concentrations that can be reached in the mammalian central nervous 
system after its administration (Chipana et al., 2008a). Also, similarly to nicotine, 
MDMA induces nAChR up-regulation in PC12 cells and in rat brain, where it also 
potentiates the regulatory effects of nicotine (García-Ratés et al., 2007; Pubill et al., 
2013). 
MDMA’s interaction with nAChR might account for some clinical features of this 
drug such as fasciculation and muscle cramps, which occur especially in MDMA 
abusers after high-dose intake (Klingler et al., 2005). Moreover, tobacco is one of the 
most widely consumed drugs and MDMA abusers very often smoke (Scholey et al., 
2004); thus, a pharmacodynamic interaction between nicotine and MDMA can be 
expected and could have several consequences that will be suggested at a later point in 
this text.  
This study was undertaken to determine whether nAChR are involved in the 
behavioral sensitization and addictive potential of MDMA. DHβE (antagonist) and 
varenicline (partial α4β2 nAChR agonist and full α7 nAChR agonist; Mihalak et al., 
2006; Rollema et al., 2007) were associated with MDMA in order to investigate the 
involvement of heteromeric nAChRs on its effects. Also, the effect of a chronic 
pretreatment with nicotine on MDMA addictive effects was investigated. We focused 
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on the locomotor hyperactivity induced by MDMA as an indicator of its 
psychostimulant effect and on the conditioned place preference (CPP) paradigm to 
assess its addictive properties. Also, we investigated the changes in the density of 
homomeric and heteromeric nAChRs in determined brain areas as a possible 
consequence of the treatment that could be related with the observed behavioural 
effects.  
2. Material and Methods. 
2.1. Animals and treatment groups 
Data were collected from adult male Swiss CD-1 mice (Charles River, Barcelona, 
Spain) weighing 24 to 30 g at the beginning of the experiments (first drug 
administration). They were housed three per cage under standard laboratory conditions 
(21 ± 1 ºC room temperature and a 12-h light/dark cycle from 8:00 am to 8:00 pm). 
Animals had free access to food (standard laboratory diet, PANLAB SL, Barcelona, 
Spain) and drinking water. All experimental procedures were conducted between 9:00 
am and 5:00 pm and were in compliance with the guidelines of the European 
Community Council (86/609/EEC) and approved by the Animal Ethics Committee of 
the University of Barcelona under the supervision of the Autonomous Government of 
Catalonia. Efforts were made to minimize suffering and reduce the number of animals 
used.  
In our experiments we administered MDMA at doses closely related to its 
recreational use in humans rather than at high doses that would lead to neurotoxic 
effects. 
Mice were assigned randomly to one of six treatment groups: Saline (saline i.p. + 
saline s.c.), MDMA (saline i.p. + MDMA s.c.), DHβE (DHβE i.p. + saline s.c.), 
DHβE+MDMA (DHβE i.p. + MDMA s.c.), VAR (saline i.p. + varenicline s.c.), 
VAR+MDMA (varenicline i.p. + MDMA s.c.). Doses and schedule are detailed below. 
Prior to experimentation, all of the animals received two habituation sessions (48 and 
24 h before testing) that were intended to reduce the novelty and stress associated with 
handling and injection. 
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2.2. Drugs 
Drugs and reagents were obtained from the following sources: 3,4-
methylenedioxymethamphetamine hydrochloride was provided by the National Health 
Laboratory (Barcelona, Spain). Varenicline was a gift from Pfizer Laboratories (New 
York, USA). Aprotinin, DHβE, methyllycaconitine (MLA), nicotine bitartrate 
dihydrate, phenylmethylsulfonyl fluoride and sodium orthovanadate were purchased 
from Sigma–Aldrich (St. Louis, MO, USA). [3H]epibatidine was from PerkinElmer 
(Boston, MA, USA), while [3H]MLA came from American Radiolabeled Chemicals 
(St. Louis, MO, USA). Drugs were dissolved in saline (NaCl 0.9%). All other reagents 
were of analytical grade 
 
2.3. Locomotor Activity 
This test was used to assess the psychostimulant effects of MDMA along the 
treatment and its modulation by nicotinic drugs. 
 
2.3.1. Drug treatment 
According to its treatment group allocation, each animal received pretreatment with 
either saline (5 ml/Kg), DHβE (1 mg/Kg) or varenicline (0.3 mg/Kg), given 
intraperitoneally, 15 min prior to saline or MDMA (5 mg/Kg), given subcutaneously, 
for 10 consecutive days. These doses were chosen based on previous reports (Camarasa 
et al., 2009; Kim et al., 2011). We administered MDMA at a 5 mg/Kg dose because, 
although it is relatively low, it induces robust behavioral activation (Ball et al., 2009). 
Once the 10-day repeated treatment phase was completed, all of the animals remained in 
their home cages for a 14-day drug-free period (days 11-24). On day 25, all of the mice 
were accordingly challenged with either a dose of saline or DHβE or varenicline plus 
saline or MDMA to assess for conditioned hyperactivity. Locomotor activity was 
measured on days 1, 10 and 25. To evaluate the development of behavioral sensitization 
we compared data from day 1 vs day 10 or day 25 of the same group . 
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2.3.2. Measurement 
On the different testing days and immediately after the i.p. injection (saline or 
MDMA), the mice were placed in a plexiglas cage. This cage constituted the activity 
box that was placed inside a frame system of two sets of 16 infrared photocells 
(LE8811, PANLAB SL, Barcelona, Spain) mounted according to the x, y axis 
coordinates and 1.5 cm above the wire mesh floor. The registration of horizontal 
locomotor activity then began. Occlusions of the photo beams were recorded and sent to 
a computerized system (SedaCom32, PANLAB SL, Barcelona, Spain). The interruption 
counts (beam breaks), in a 10-min block, were used as a measure of horizontal 
locomotor activity. The locomotor activity of each mouse was monitored over 180 min. 
All experiments were conducted between 9:00 am and 3:00 pm. Results are expressed 
as cumulative breaks per mouse for 180 min or as AUC (area under the curve), which 
was measured as the total changes from baseline at each recording interval over the total 
measuring time.  
 
2.4. Radioligand binding experiments 
2.4.1.  Tissue Sample Preparation 
Six hours after the challenge with MDMA on day 10 or on day 25, 5-6 animals per 
group were killed by cervical dislocation, then decapitated and the brains rapidly 
removed from the skull. Cortex, striata and hippocampus were quickly dissected out, 
frozen on dry ice and stored at -80 ºC until use. When required, tissue samples were 
thawed and homogenized at 4 ºC in 10 volumes of buffer consisting of 5 mM Tris-HCl, 
320 mM sucrose and protease inhibitors (aprotinin 4.5 mg/ml, 0.1 mM PMSF and 1 mM 
sodium orthovanadate), pH 7.4, with a Polytron homogenizer. The homogenates were 
centrifuged at 15,000 × g for 30 min at 4 °C. The pellets were resuspended in fresh 
buffer and incubated at 37 °C for 10 min to remove endogenous neurotransmitters. The 
protein samples were subsequently re-centrifuged and washed two additional times. The 
final pellets (crude membrane preparations) were resuspended in 50 mM Tris–HCl 
buffer plus protease inhibitors and stored at −80 °C until later use in radioligand binding 
experiments. Protein content was determined using the Bio-Rad Protein Reagent (Bio-
Rad Labs. Inc., Hercules, CA, USA), according to the manufacturer’s instructions. 
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2.4.2. [3H]Epibatidine Binding.  
[3H]Epibatidine binding was used to label heteromeric nAChR, which in CNS are 
mainly α4β2. Binding of [3H]epibatidine to brain membranes from cortex and striatum 
was measured as described previously (Chipana et al., 2008b). Briefly, experiments 
were carried out in glass tubes containing 1 nM [3H]epibatidine (55.5 Ci/mmol)―at this 
concentration primarily α4β2 receptors are labeled (Avila et al., 2003)―and incubation 
was carried out for 3 h at 25 °C. The incubation buffer was 50 mM Tris-HCl plus 
protease inhibitors. Non-specific binding was determined in the presence of 300 μM 
nicotine. Binding was terminated by filtration, and data were treated as described below. 
2.4.3. [3H]MLA Binding.  
[3H]MLA binding was used to quantify homomeric α7 nAChR. Binding of [3H]MLA 
to brain hippocampal membranes was measured as described by Davies et al. (1999). 
Briefly, 0.25 ml of membranes (containing 200 μg of brain membranes) was incubated 
in borosilicate glass tubes with 2 nM [3H]MLA (60 Ci/mmol),  in a final volume of 0.5 
ml for 2 h at 4 °C. The incubation buffer consisted of 50 mM Tris–HCl, 120 mM NaCl, 
2 mM CaCl2, 1 mM MgSO4 and 0.1% bovine serum albumin. Non-specific binding was 
determined from tubes containing 1 μM unlabeled MLA. Incubation was completed by 
rapid filtration under vacuum through Whatman GF/B glass fiber filters (Whatman Intl. 
Ltd., Maidstone, U.K.) pre-soaked in 0.5% polyethyleneimine. Tubes and filters were 
washed rapidly 3 times with 4 ml ice-cold 50 mM Tris–HCl and the radioactivity 
trapped was measured by liquid scintillation spectrometry. Specific binding was 
calculated as the difference between the radioactivity measured in the absence (total 
binding) and in the presence (non-specific binding) of the excess of non-labeled ligand, 
and expressed as the percentage of that obtained from saline-treated mice. 
 
2.5. Conditioned Place Preference (CPP) Paradigm. 
The place conditioning protocol used was non-biased (Robledo et al., 2004). The 
apparatus was composed of three distinct compartments separated by manually operated 
doors. The central compartment (corridor) measured 27x10x25 cm (w x d x h) and 
served as a thoroughfare between the two pairing sides. The pairing compartments are 
20x20x25 cm (w x d x h). One compartment had black and white checkered walls with 
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a smooth and shiny floor. The other compartment had white and light blue painted walls 
and rough flooring. The light intensity within the conditioning chambers was 30 lux. 
CPP was performed in three phases: preconditioning, conditioning and test. During the 
pre-conditioning phase (day 1), naive or nicotine pre-treated mice were placed in the 
middle of the corridor and had free access and roam among the three compartments of 
the apparatus for 20 min. The time spent in each compartment was recorded by 
computerized monitoring software (Smart Junior, PANLAB SL, Barcelona, Spain). 
During the conditioning phase (days 2, 4, 6 and 8), mice were treated with MDMA (3 
and 10 mg/kg, s.c.), or saline, 20 min before being confined into one of the two 
conditioning compartments for 30 min. On days 3, 5, 7 and 9 of the conditioning phase, 
animals received saline and were confined to the opposite compartment. The animals 
were exposed to only one pairing per day and treatments were counterbalanced to assure 
that some animals received MDMA in the black and white compartment while others 
received MDMA in the white and light blue compartment.  
Control animals received saline every day. For conditioning studies with DHβE or 
varenicline, these drugs or saline were administered intraperitoneally 15 min before 
MDMA, at doses previously described as effective in antagonizing nicotine-induced 
CPP (2 mg/Kg) (Biala et al., 2010; Walters et al., 2006). The test phase (day 10) was 
conducted identically to the preconditioning phase; animals were drug-free and had free 
access to the three compartments for 20 min.  
To investigate whether nicotine (administered in a previous chronic treatment) 
potentiates MDMA-induced CPP, nicotine was given intraperitoneally at a dose of 2 
mg/Kg (Dougherty et al., 2008) b.i.d. for 14 days. The day after, nicotine was 
withdrawn and preconditioning for CPP was started with MDMA at a dose of 3 mg/Kg 
as above. A preference score was expressed in seconds and calculated for each animal 
as the difference between the times spent in the drug-paired compartment in the post-
test minus the time spent in the pre-conditioning phase. 
 
2.8. Statistical Analysis 
All data are expressed as mean ± standard error of the mean (S.E.M.). Differences 
between groups were compared using two-tailed one-way analysis of variance 
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(ANOVA). Significant (p<0.05) differences were then analyzed by Tukey’s post hoc 
test for multiple means comparisons, where appropriate. AUC values were calculated by 
nonlinear regression using GraphPAD Prism (GraphPAD software, San Diego, CA, 
USA). All statistic calculations were performed using Graph Pad Instat (GraphPad 
software, San Diego, CA, USA).  
 
3. Results 
3.1. Effect of nAChR ligands on induction of behavioral sensitization to MDMA 
Locomotor activity was used to measure behavioral sensitization to MDMA in the 
different treatment groups through time. On day 1 an acute challenge of MDMA (5 
mg/Kg) produced significantly greater locomotor activity than saline alone (total breaks 
(TB): 3423 ± 267 saline, 4870 ± 244 MDMA, p<0.001). This psychostimulant effect 
was fully abolished by pretreatment with DHβE or varenicline (F5,89=6.92, p<0.001, see 
figure 1, table 1). DHβE and VAR control groups revealed the absence of effect of these 
drugs alone on locomotor activity. 
Similarly, on day 10, one-way ANOVA showed a significant effect of treatment 
(F5,89=23.04, p<0.001). Daily exposure to MDMA or DHβE+MDMA or 
varenicline+MDMA revealed sensitization, expressed as a significant increase in the 
psychostimulant effect of MDMA. The inhibitory effect of DHβE and varenicline 
observed in the acute challenge of MDMA on day 1 was not present after 10 
consecutive days of treatment. Day10/day1 ratio of total breaks (F2,41=175.92, p<0.001; 
136.32 ± 3.24% MDMA, 169.23 ± 3.10% DHβE+MDMA and 225.29 ± 2.59% 
VAR+MDMA) revealed that these drugs enhanced rather than attenuated this early 
sensitization. As on day 1 the animals treated with DHβE/VAR alone denoted the 
absence of effect of these antagonists on locomotor activity on day 10. 
 
Behavioral sensitization was monitored up to 2 weeks after the discontinuation of 
MDMA treatment. Analysis of results on day 25 to assess conditioned hyperactivity 
showed an overall significant difference among treated groups (F5,74=37.25, p<0.001, 
see figure 1, table 1). A challenge dose of MDMA induced a stronger behavioral 
response than that administered on day 10 (day 25: 8075 ± 404; day 10: 6639 ± 332; 
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p<0.01). DHβE- or varenicline- pretreated mice showed a response on day 25 that did 
not differ from that on day 10 (see figure 1). These results were assessed when 
analyzing day25/day10 ratio of total breaks (F2,23=7.12, p<0.01: 118.12±2.49% MDMA, 
105.81±3.02% DHβE+MDMA p<0.01 vs MDMA and 108.00±2.86% VAR+MDMA 
p<0.05 vs MDMA). Differences between total breaks on day 25 and total breaks on day 
10, confirms the results (F2,23=29.15 p<0.001; 1436±163 MDMA, 128±12 
DHβE+MDMA, varenicline+MDMA=193±18). 
 
3.2. Effect of nAChR ligands on the density of nicotinic receptor subtypes in different 
mouse brain areas 
Due to the effects observed in locomotor activity experiments, the density of nAChR 
was measured in several brain areas of the same animals in order to establish a possible 
relationship between such effects and changes in receptor populations. 5 animals of 
each treatment group were killed on day 10 after treatment and locomotor activity 
measurement, while the rest were kept to obtain the results on day 25. 
Treatment with MDMA, DHβE or varenicline for 10 days induced a significant 
increase in [3H]epibatidine binding in cortex, compared with those receiving saline 
alone (F5,34=2.908, p<0.05)  . DHβE also induced such an increase in the striatum. In 
this area, MDMA did not modify [3H]epibatidine binding and did not alter the increase 
in heteromeric nAChR expression induced by DHβE. Moreover, pretreatment with 
varenicline significantly reduced [3H]epibatidine binding in mouse striatum; this was 
not altered by MDMA (F5,29=27.231, p<0.001) (Fig. 2B).  
After the 14-day drug-free period, the mice treated previously with MDMA (but not 
those pretreated only with DHβE or varenicline alone), showed a significant increase in 
heteromeric nAChR density in cortex and striatum. The cortical increase in 
[3H]epibatidine binding was not present in animals which received pretreatment with 
DHβE or varenicline (F3,21=18.936, p<0.001) (Fig. 3A). Only pretreatment with DHβE 
prevented the up-regulation induced by MDMA in striatum (F3,23=3.376, p<0.05) (Fig 
3B).  
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When analyzing the density of homomeric α7 nAChR in hippocampus, where they 
are more highly expressed, no differences in receptor densities, measured as [3H]MLA 
binding, were found in MDMA-treated mice (Fig 4). 
 
3.3. Effect of nAChR ligands on the acquisition of MDMA-induced CPP 
The CPP paradigm was used to study the effect of the different treatments on the 
addictive/rewarding properties of MDMA. 
Throughout all experiments, a within-subjects comparison revealed that mice had no 
bias. Time (in seconds) spent in both compartments during pre-conditioning were 
367.58 ± 56.70 and 326.05 ± 35.69, indicating a lack of preference for either side. This 
did not significantly change in the test session (309.12 ± 35.14 and 276.19 ± 28.73) 
when saline was paired with both compartments during the conditioning phase.  
We first investigated the effect of varenicline and DHβE in the CPP induced by 
MDMA (10 mg/kg). On the test day (day 10, post-conditioning), one-way ANOVA 
revealed a significant effect of treatment (F5,36 = 4.56, p<0.01). The ability of MDMA to 
produce a CPP was assessed while some mice were under the influence of DHβE or 
varenicline (2 mg/kg) treatment, administered 15 min before the MDMA dose. Both 
reduced MDMA's ability to produce a CPP, fully blocking MDMA's effects (p<0.05 for 
varenicline and p<0.01 for DHβE vs. MDMA-treated mice) (Fig 5B). Neither DHβE 
nor varenicline alone had any effect on CPP. 
During the pre-conditioning phase and test day we measured the distance and speed 
of travel in each of the two compartments. Results corresponding to the drug-paired 
compartment are shown in Table 2 and demonstrate that treatment with MDMA during 
the conditioning phase induces an increase in locomotor activity in the test day that is 
not present in animals pretreated with varenicline or DHβE. This increase in locomotor 
activity was not accompanied by an increase in speed and confirms a psychostimulant 
effect in these animals. 
To explore the effect of a chronic nicotine treatment on the addictive behavior caused 
by a low dose of MDMA (3 mg/Kg) which is not supposed to induce CPP when given 
alone (Robledo et al., 2004), we pretreated mice with nicotine at a dose of 2 mg/Kg, 
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given subcutaneously (b.i.d.) for 14 days. This treatment induced a significant increase 
in α4β2 nAChR density in the striatum (147.98 ± 13.13%, nicotine-treated vs 100.00 ± 
10.56%, saline-treated, p<0.05, Student’s t test). This nicotine treatment schedule did 
not induce a significant CPP on its own (Dougherty et al., 2008) and, therefore, at the 
end of the nicotine treatment, animals did not show preference for either of the two 
compartments (445.85 ± 69.28 vs 551.02 ± 27.82). Repeated nicotine administration 
during the 14 days prior to pre-conditioning led to a decreased MDMA threshold for 
CPP. As reflected in Fig. 6, when animals were exposed to chronic nicotine 
pretreatment, they showed a positive preference score at a dose of MDMA (3 mg/Kg) 
that proved to be ineffective when administered alone (F2,23 = 5.808, p<0.01). 
4. Discussion 
This study examines the involvement of heteromeric nAChR in the behavioral 
sensitization as well as the addictive potential of MDMA in mice. The results indicate 
that an antagonism or a partial agonism on nAChR reduces the addiction, blocks the 
acute locomotor effects and changes the development of sensitization induced by 
MDMA. 4β2 nAChR appear to mediate these effects given that DHβE and varenicline, 
but not MLA (data not shown), antagonized the acute effects of MDMA. In fact, 
previous studies (Walters et al., 2006) have demonstrated that MLA at doses of 5 and 10 
mg/Kg (s.c), does not inhibit nicotine-induced CPP, ruling out an involvement of the α7 
nAChR in this behavior.  
The psychomotor stimulant effect of MDMA is considered subsequent to an 
extracellular increase in DA and 5-HT in the NAcc and VTA (Bankson and 
Cunningham, 2001). In a previous study we demonstrated the involvement of nicotinic 
receptor subtypes in the hyperlocomotion induced by methamphetamine (Camarasa et 
al., 2009). Here we report that the stimulant effects of an acute dose of MDMA are 
blocked by antagonists acting on α4β2 nAChR.  Nicotinic agonists can differentially 
affect neurotransmitter release in a given brain region and the magnitude of such 
responses will largely be determined by the subtype selectivity of the agonist (Rao et 
al., 2003). Nicotine activates nAChR localized in the dopaminergic nerve terminals in 
the nucleus accumbens and elicits a complex pattern of inhibitory–stimulatory effects 
on locomotion (Avale et al., 2008).  
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Although there are subtle differences between MDMA and other commonly abused 
amphetamines, a clear overlap in the behavioral pharmacology of MDMA and other 
amphetamine-like compounds can be found, especially in the induction of behavioral 
excitation. In rodents, this effect, called behavioral sensitization, persists many months 
after the last administration, thus mimicking long-term sensitivity to drugs observed in 
human addicts. Expression of this persistent drug-induced behavioral sensitization has 
been suggested to contribute to craving and high relapse rates in addicts (Robinson and 
Berridge, 2003). Studies of the neurobiological basis of behavioral sensitization have 
focused on the increased capacity of these drugs to release dopamine in the midbrain 
dopamine system (Cadoni et al., 2000) although multiple limbic-associated areas such 
as the prefrontal cortex provide the excitatory cortical innervation to the NAcc (Kita and 
Kitai, 1990). This dopaminergic system mediates locomotor stimulation as well as the 
ability of drugs to elicit craving and lead to abuse.  
When MDMA was administered daily for 10 consecutive days, there was an increase 
in the hyperlocomotion induced by this drug on day 10 respect with that measured on 
day 1 (early behavioral sensitization). These results are in agreement with those 
previously described in rats (Kalivas et al., 1998) demonstrating that repeated 
administration of MDMA over the course of ten days produces sensitization to the 
behavioral stimulant effects of MDMA. Furthermore, the behavioral sensitization in 
mice was found to be highest after a 2 week-period following the discontinuation of 
MDMA treatment, (a challenge dose of MDMA showed a stronger behavioral response 
than on day 10) demonstrating that the treatment schedule of MDMA used in this study 
induces not only an early but also a delayed sensitization that can be modulated by 
drugs acting on α4β2 nAChR. 
Neither DHβE nor varenicline blocked but rather enhanced the development of early 
behavioral sensitization by MDMA, conversely to the inhibitory effect observed in the 
acute challenge (day 1). When comparing the ratios D10/D1 of the different groups, a 
potentiation was revealed for those treated with MDMA plus DHβE or varenicline. In 
other words, the groups receiving MDMA plus the nicotinic ligand showed a day-to-day 
greater increase in locomotion than the group receiving MDMA alone.    
 
The increased delayed sensitization to MDMA was prevented when it was 
administered together with either the α4β2 nAChR antagonist (DHβE) or the partial 
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agonist (varenicline). It is known that nAChR ligands regulate sensitization to stimulant 
drugs such as d-amphetamine and cocaine. For instance, DHβE, a high-affinity 
competitive antagonist of 4 subunit-containing nAChR, attenuates the induction of 
locomotor sensitization to d-amphetamine, cocaine, ephedrine and methylphenidate in 
mice and rats (Karler et al. 1996; Miller and Segert 2005; Schoffelmeer et al. 2002; 
Woorters and Bardo, 2009). Additionally, the sensitizing effect of acute nicotine on 
amphetamine-stimulated behavior and dopamine efflux requires activation of β2 
subunit-containing nAChRs (Kim et al., 2011).  
Varenicline is an effective aid in smoking cessation. This drug, by acting on α4β2 
nAChR, stimulates dopamine release when the basal tone is depressed and 
simultaneously blocks the effects of a full agonist when simultaneously present. Partial 
agonists aim to provide a low-to-moderate level of dopamine stimulation to reduce 
craving and withdrawal symptoms. When varenicline is administered to nicotine-
sensitized rats, it reduces the expression of nicotine sensitization (Zaniewska et al., 
2008). Similarly, in our experiments, varenicline inhibited the increase in the delayed 
sensitization observed on day 25. 
Due to the described dynamic plasticity of nAChR after treatment with nicotinic 
ligands, we assessed the density of heteromeric (mainly α4β2) and homomeric α7 
receptors through radioligand binding studies. The results showed that early 
sensitization on day 10 was accompanied by changes in α4β2 nAChR density in certain 
brain areas. MDMA induced in cortex, but not in the striatum, a significant increase in 
α4β2 nAChR that was not blocked by DHβE or varenicline. However, the results on day 
25 correlate with the in vivo effects: although these animals had a 14-day drug-free 
period, the increased α4β2 nAChR density in cortex and striatum was still present in the 
MDMA group, but not in the animals co-treated with DHβE. Varenicline appears to do 
the same in the cortex. From these results it can be deduced that the α4β2 nAChR 
subtype is involved in the early and delayed sensitization elicited by MDMA. If 
treatment leads to an increase in α4β2 nAChR subtype population in cortex, the 
sensitization takes place. By contrast, when this up-regulation is prevented, sensitization 
is attenuated. The role of the cortex in sensitization is not an exception as it is known 
that the prefrontal cortex and the hippocampus exhibit converging projections to the 
NAcc and have functional reciprocal connections via indirect pathways (Day et al., 
1991; Goto and Grace, 2008). Medial prefrontal neurons, including those projecting to 
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the NAcc (McGinty and Grace, 2008), are also excited by conditioned stimuli 
(Laviolette et al., 2007) and Ball et al (2009) demonstrating that long-lasting locomotor 
sensitization to MDMA is accompanied by reorganization of synaptic connectivity, not 
only  in NAcc, but also in the medial prefrontal cortex. 
 
Effects derived from changes in α7 nAChR population can be ruled out from present 
binding studies. The difference between the effects of DHβE and varenicline can be 
explained by their different pharmacological profile. 
 
Once the correlation between nAChR and behavioral sensitization to MDMA was 
demonstrated, we examined the effect of α4β2 nAChR ligands as well as that of a 
nicotine chronic treatment on the CPP score induced by MDMA. In this study we 
provide evidence that MDMA at a dose of 10 mg/kg, but not 3 mg/Kg, causes positive 
CPP in mice. These results are in agreement with those of Salzmann et al. (2003) and 
Robledo et al. (2004). Bilsky et al. (1998) demonstrated that the CPP induced by 
MDMA was effectively blocked by the dopamine release inhibitor CGS10746B. These 
results and those of Vidal-Infer et al. (2012) demonstrate that, in mice, the dopaminergic 
system is involved in the acquisition and expression of MDMA-produced CPP. 
Moreover, results of the present study provide pharmacological evidence of the 
involvement of the 4-containing nAChR in the CPP induced by MDMA, as this effect 
was antagonized by DHβE and varenicline.  
Acute nicotine challenge induces behavioral sensitization to amphetamines (Birrell 
and Balfour, 1998, Jutkiewicz et al., 2008) and consequently can enhance its addictive 
potential. In this study we used a chronic nicotine treatment in order to increase the 
density of α4β2 nAChR (Dougherty et al., 2008). It is important to note that nicotine 
treatment took place previously and this drug was not present during the CPP 
experiments with MDMA, avoiding any interaction on the test day. Abstinence signs of 
nicotine are dose-dependent and appear at doses equal to or higher than 6.3–8 
mg/kg/day (Isola et al., 1999, Gould et al., 2012) and not at 6 mg/kg/day or lower 
(Damaj et al., 2003), as in our experiments. These signs last for a maximum of 3-4 days 
(Zhang et al., 2012) and are supplemented with deficits in contextual learning (Gould et 
al., 2012). In the present study, sustained exposure to nicotine significantly increased 
MDMA rewarding in the CPP paradigm. While MDMA at a low dose (3mg/kg) did not 
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induce CPP on its own, this dose of MDMA showed a very significant preference score 
in nicotine-pretreated mice.   
As in the behavioral sensitization experiments, this increase in the CPP score caused 
by MDMA runs parallel to an increase in α4β2 nAChR density induced by nicotine, 
pointing to an up-regulation of these receptors as an additional factor in  MDMA’s 
reinforcing effect. The up-regulated nAChR could mediate enhanced synaptic 
transmission when stimulated by local and brief releases of ACh at synapses. 
Stimulation of dopamine neurons in the VTA via the α4β2 nAChR leads to an increase 
of dopamine in the NAcc that plays a crucial role in drug reward as measured by CPP 
(Di Chiara and Imperato, 1988). Consequently, the modulation of dopamine release by 
means of α4β2 nAChR activation could result in a modification of the CPP induced by 
MDMA. Although animals were not under the effect of nicotine when tested in the CPP 
paradigm, and despite the very low dosage of this stimulant administered during the 
pretreatment phase, we cannot rule out an influence of nicotine withdrawal in the first 
days of the conditioning phase. 
The influence of chronic nicotine treatment on MDMA effects extends not only to 
CPP but also to its hyperlocomotion properties. In previous studies (Camarasa et al., 
2009) we have described that nicotine, when administered in a chronic low-dose 
schedule, significantly potentiates the methamphetamine-induced increase in locomotor 
activity and rearing. These results suggest that up-regulation of nAChR leads to a very 
significant potentiation of the increase in locomotor activity induced by this drug. 
Similar results were obtained for MDMA-induced hyperlocomotion using the same 
nicotine pretreatment than in the study with methamphetamine (a 30% potentiation,, 
unpublished results).  
 
A great number of MDMA consumers also smoke concomitantly (Scholey et al., 
2004). In view of results obtained in the present paper it can be deduced that smoking 
can increase neuronal sensitization to MDMA and its addictive potential, making 
MDMA-users more susceptible to addiction. Although further research must be done on 
this subject, our results suggest that α4β2 nAChRs are a potential target towards treating 
nicotine and MDMA polyabuse. Although DHβE is a useful pharmacological tool for 
preclinical studies on nAChR, it is not adequate for clinical use due to its toxicity: it can 
produce neuromuscular blockade, hypotension and has a vey narrow dosage window 
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(the i.p. DL50 in mice is 4.5 mg/kg, Megirian et al., 1955). Also DHβE, as a pure 
antagonist, can precipitate nicotine abstinence syndrome (Malin et al., 1998). 
Conversely varenicline, as a marketed drug for smoking cessation with a good security 
profile, should be taken into consideration as a possible candidate drug. 
 
5. Conclusion 
In summary, although it is well known that nAChRs are a pharmacological target for 
understanding the neurotoxic effects of amphetamine derivatives (Chipana et al., 
2008c), they are also involved in other behavioral effects of these drugs such as 
hyperlocomotion and addictive properties. This paper demonstrates the involvement of 
specific 4-containing nAChR subtypes by using specific modulators of these receptors.  
Our results point out that effects induced by MDMA such as locomotor sensitization 
and addictive potential, both related with the release of dopamine, are modulated by 
DHβE and varenicline. Consequently, varenicline, a commercial drug used to treat 
tobacco addiction, could also be considered for treating MDMA abuse. Finally, these 
results may have clinical implications because MDMA abusers are often smokers; in 
this regard, varenicline would be the first useful drug to simultaneously treat both 
tobacco and MDMA abuse. 
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Figure captions 
Fig 1. 
Cumulative breaks after 180 min for the effect of saline, DHβE (1 mg/Kg), or 
varenicline (VAR) (0.3 mg/Kg) on saline/MDMA (5 mg/Kg)-induced hyperlocomotion. 
Locomotor activity was measured on day 1 (acute challenge), day 10 (after a daily dose 
for ten days) and day 25 (acute challenge of saline, DHβE or varenicline  plus  saline or 
MDMA after 14-day withdrawal). Data are expressed as mean ± SEM. *p<0.05, 
**p<0.01, ***p<0.001, significantly different from day 1 of the same treated group. 
##p<0.01 significantly different from day 10 of the same treated group.  p<0.001 
significantly different from saline day 1.  
 
Fig 2. 
Effect of treatment with saline, DHβE (1 mg/Kg), or varenicline (VAR) (0.3 mg/Kg) 
plus saline or MDMA (5 mg/Kg) during 10 consecutive days on α4β2 nAChR density 
(measured as [3H]epibatidine binding) in mouse cortex (panel A) or striatum (panel B). 
Data are expressed as mean ± SEM from the values obtained from 5-6 animals per 
group. *p<0.05 and **p<0.01, significantly different from saline-treated group. 
 
Fig 3. 
 
Effect of a 14 day withdrawal after a 10 consecutive day treatment with saline, DHβE (1 
mg/Kg), or varenicline (VAR) (0.3 mg/Kg) plus saline or MDMA (5 mg/Kg) on α4β2 
nAChR density (measured as [3H]epibatidine binding) in mouse cortex (panel A) or 
striatum (panel B). On day 25, mice were killed 6 h after receiving the assigned 
treatment and their brains were used for this experiment. Data are expressed as mean ± 
SEM from the values obtained from 5-6 animals per group. *p<0.05 significantly 
different from saline-treated group. 
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Fig 4. 
 
Effect of MDMA (5 mg/Kg) alone for 10 consecutive days (day 10) or after a 14 day 
withdrawal period (day 25) on α7 nAChR density (measured as [3H]MLA binding) in 
mouse hippocampus. Data are expressed as mean ± SEM from the values obtained from 
5-6 animals per group 
 
Fig 5. 
 
Effect of DHβE (2 mg/Kg) and varenicline (VAR) (2 mg/Kg) alone and on MDMA (10 
mg/Kg)-induced conditioned place preference. The x-axis represents the treatment 
group and the y-axis represents the preference score (test day minus preconditioning 
day) in seconds. **p<0.01, significantly different from saline-treated group; #p<0.05 
and ##p<0.01, significantly different from the corresponding value of MDMA-treated 
group. 
 
Fig 6. 
 
Effect of a 14 day chronic nicotine pretreatment (2 mg/Kg, b.i.d.) on the conditioned 
place preference assay on MDMA (3 mg/Kg). Data are expressed as mean ± SEM. 
**p<0.01, significantly different from saline- or MDMA-treated groups. 
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Table 2.- Distance travelled and the speed in the drug-paired compartment measured in 
the pre-conditioning day and in the test day (absence of drug treatment). Results are 
expressed as mean ± standard error of the mean from 8 different animals       
 
Drug treatment Distance travelled (cm) Speed (cm/s) 
Pre-conditioning Test Pre-conditioning Test 
Saline 1112.23 ± 176.39 1120.03 ± 143.73 3.30 ± 1.19 2.90 ± 0.97 
MDMA 1329.62 ± 51.62 2063.11 ± 55.46** 3.63 ± 0.23 3.04 ± 0.43 
VAR+MDMA 1660.90 ± 178.57 1953.87 ± 154.16 4.14 ± 0.91 3.66 ± 0.66 
DHBE+MDMA 1664.25 ± 61.64 1872.36 ± 151.60 3.62 ± 0.24 3.71 ± 0.13 
 
**P<0.01 vs. the corresponding value of the preconditioning day (paired Student t-test). 
Table 2
